12 terminated. 12 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Terminated 12 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement Mirabegron, Placebo - Urinary Bladder, Overactive, Pain | Phase 2 | Terminated | Southern Illinois University | 11 | 2015-05-01 | 2023-06-13 |
| Cystoscopic Ablation Via RF Energy Clinical Trial Amphora OAB Device - Overactive Bladder | Phase 1 / Phase 2 | Terminated | Amphora Medical, Inc. | 63 | 2015-02-01 | 2019-05-07 |
| Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients BTX mixed with TC-3 Gel - Overactive Bladder | Phase 1 / Phase 2 | Terminated | UroGen Pharma Ltd. | 3 | 2014-07-01 | 2016-03-01 |
| Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder Bryophyllum - Overactive Bladder, Urge Urinary Incontinence | Phase 2 / Phase 3 | Terminated | University of Zurich | 9 | 2014-05-01 | 2017-10-26 |
| A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity Darifenacin - Neurogenic Detrusor Overactivity | Phase 2 | Terminated | Warner Chilcott | 35 | 2008-10-07 | 2022-06-09 |
| Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder Botulinum toxin type A, Placebo - Overactive Bladder | Phase 2 | Terminated | Ipsen | 81 | 2008-02-01 | 2019-11-22 |
| Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Normal saline (Placebo); botulinum toxin Type A (200U), botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U) - Overactive Bladder | Phase 2 | Terminated | Allergan | 74 | 2007-12-01 | 2015-10-02 |
| Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity Darifenacin (BAY79-4998) - Multiple Sclerosis, Overactive Detrusor | Phase 2 | Terminated | Bayer | 7 | 2007-02-01 | 2014-12-02 |
| ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB) ELB245, Tolterodine - Overactive Bladder, Urinary Incontinence | Phase 2 | Terminated | elbion AG | 275 | 2007-02-01 | 2007-08-08 |
| Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity AV608 - Overactive Bladder Syndrome | Phase 2 | Terminated | Avera Pharmaceuticals | 62 | 2006-06-01 | 2008-02-25 |
| Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients GW679769 - Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder | Phase 2 | Terminated | GlaxoSmithKline | 1 | 2006-01-01 | 2015-04-17 |
| NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder type A botulinum toxin - Overactive Bladder | Phase 2 | Terminated | University Hospital, Rouen | 80 | 2003-12-01 | 2015-03-24 |
Urinary Incontinence, Urge (3) · Spinal Cord Injuries (2) · Lower Urinary Tract Symptoms (1) · Meningomyelocele (1) · Multiple Sclerosis (1) · Pain (1) · Urinary Incontinence (1)
Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Male Urogenital Diseases (12) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12) · Urinary Bladder Diseases (12) · Urogenital Diseases (12) · Urologic Diseases (12) · Urological Manifestations (12) · Lower Urinary Tract Symptoms (11) · Urination Disorders (4) · Nervous System Diseases (3) · Urinary Incontinence (3) · Central Nervous System Diseases (2) · Spinal Cord Diseases (2)
Botulinum Toxins, Type A (3) · darifenacin (2) · Saline Solution (1) · Tolterodine Tartrate (1) · abobotulinumtoxinA (1) · casopitant (1) · mirabegron (1)
Allergan (1) · Amphora Medical, Inc. (1) · Avera Pharmaceuticals (1) · Bayer (1) · GlaxoSmithKline (1) · Ipsen (1) · Southern Illinois University (1) · University Hospital, Rouen (1) · University of Zurich (1) · UroGen Pharma Ltd. (1) · Warner Chilcott (1) · elbion AG (1)
Germany (3) · United States (3) · Belgium (2) · France (2) · Netherlands (2) · United Kingdom (2) · Canada (1) · Colombia (1) · Czechia (1) · Egypt (1) · Greece (1) · India (1) · Israel (1) · Italy (1) · Lebanon (1)
Ahmed El-Zawahry, MD (1) · Ami Sidi, Prof MD (1) · Herman Ellman, MD (1) · Joao Siffert, MD (1) · Linda Cardozo, MD FRCOG (1) · Martin Michel, Prof. (1) · Roger Demochowski, MD (1)